In a significant development for the global pharmaceutical industry, Lupin Limited (Lupin) has announced its latest achievement: receiving approval from the United States Food and Drug Administration (U.S. FDA) for its Abbreviated New Drug Application (ANDA) for Bromfenac Ophthalmic Solution, 0.075%. This approval marks a pivotal step for Lupin, granting them the rights to manufacture […]
Global pharmaceutical titan, Lupin Limited, has officially declared its success in securing the esteemed approval from the United States Food and Drug Administration (FDA). This sanction is specific to Lupin’s Abbreviated New Drug Application (ANDA) for Bromfenac Ophthalmic Solution at a concentration of 0.09%. With this, Lupin is now green-lighted to market its version as […]
